Particle.news
Download on the App Store

Huge Turnout Crowds Galicia Hospitals as RSV Vaccine Trial Opens to All Adults

The randomized, real-world study aims to generate evidence for possible adult calendar inclusion as early as 2028.

Overview

  • Regional health service Sergas expanded the Sincigal trial to residents aged 18 and over after an SMS callout drew heavy weekend participation at 14 public hospitals.
  • Queues stretched up to two hours in cities including Vigo, A Coruña and Santiago, prompting hospitals to add nursing posts and keep vaccination lines running without breaks.
  • Enrollment is randomized by computer with roughly a 50% chance to receive Pfizer’s Abrysvo and 50% to join the control group, so many volunteers left without being vaccinated.
  • Authorities reported 5,423 recruits on the first day across Galicia, including 1,089 in A Coruña, 777 in Santiago and 717 in Vigo, with sign-ups continuing through January.
  • The pragmatic trial tracks outcomes through health records to assess whether adult vaccination reduces RSV hospitalizations and to inform policy, building on Galicia’s infant RSV success.